Macrophage colony-stimulating factor

AmMax Bio to Present at the 2nd Annual LifeSci Partners Private Company Summer Symposium

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Medical specialties, Cytokines, Colony stimulating factor 1 receptor, Macrophage colony-stimulating factor, Macrophage, Idiopathic pulmonary fibrosis, Fibrosis, Pulmonary fibrosis, Cytokine

A potent inhibitory CSF1R monoclonal antibody, AMB-05X represents a therapeutic platform targeting serious macrophage-driven inflammatory, fibrotic and neovascular diseases.

Key Points: 
  • A potent inhibitory CSF1R monoclonal antibody, AMB-05X represents a therapeutic platform targeting serious macrophage-driven inflammatory, fibrotic and neovascular diseases.
  • The CSF1 receptor, via its binding to two regulatory cytokines, CSF1 and IL-34, is critically involved in the regulation of macrophages and related cells in multiple biological processes across many organ systems, making it an attractive target with broad therapeutic applications.
  • Overactivation of the CSF1/IL-34 CSF1R axis substantially contributes to the inflammatory, fibrotic and neovascular characteristics inherent in many diseases.
  • AmMax is enrolling patients in a Phase 2 clinical program for tenosynovial giant cell tumor (TGCT) and has achieved nonclinical proof-of-concept in both neovascular age-related macular degeneration (nAMD) and idiopathic pulmonary fibrosis (IPF).

Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

Retrieved on: 
Tuesday, May 4, 2021
Life sciences, Pharmaceutical industry, Biotechnology, Health sciences, Antineoplastic drugs, Cytokines, Biopharmaceutical, Pharmacy, Medication, Histone deacetylase inhibitor, Macrophage colony-stimulating factor

b'WALTHAM, Mass., May 4, 2021 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax\'s management team will host a conference call and live audio webcast at 4:30 p.m.

Key Points: 
  • b'WALTHAM, Mass., May 4, 2021 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.\nIn connection with the earnings release, Syndax\'s management team will host a conference call and live audio webcast at 4:30 p.m.
  • ET on Tuesday, May 11, to discuss the Company\'s financial results and provide a general business update.\nThe live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company\'s website at www.syndax.com .
  • The Company\'s pipeline includes SNDX-5613, a highly selective inhibitor of the MeninMLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor.
  • For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn .\n'

AmMax Bio to Present at the BofA Securities 2021 Virtual Healthcare Conference

Retrieved on: 
Thursday, April 29, 2021
Branches of biology, Medical specialties, Medicine, Tyrosine kinase receptors, Colony stimulating factor 1 receptor, Cytokines, Macrophage colony-stimulating factor, Monoclonal antibody, Fibrosis

b'REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (\xe2\x80\x9cAmMax\xe2\x80\x9d), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will present at the BofA Securities 2021 Virtual Healthcare Conference.

Key Points: 
  • b'REDWOOD CITY, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (\xe2\x80\x9cAmMax\xe2\x80\x9d), a private clinical-stage biopharmaceutical company focused on developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced that it will present at the BofA Securities 2021 Virtual Healthcare Conference.
  • A long-acting AMB-05X with strong anti-fibrotic activity will reduce patient treatment burden and is expected to limit vision loss from macular fibrosis.
  • Overactivation of the CSF1/IL-34 \xe2\x80\x93 CSF1R axis substantially contributes to the inflammation and fibrosis inherent in many diseases.
  • Thus, the potent inhibition of CSF1R activity by AMB-05X represents a novel and powerful means of therapeutic intervention via its dual action.\n'

Humanigen to Present at Roth Conference

Retrieved on: 
Friday, March 5, 2021
Professional services, Health, Infectious diseases, Finance, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Cell biology, Cytokines, Granulocyte-macrophage colony-stimulating factor, EMR1, Macrophage colony-stimulating factor, Coronavirus disease

Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

Key Points: 
  • Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
  • In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.
  • For more information, visit www.humanigen.com and follow Humanigen on LinkedIn , Twitter and Facebook .

AmMax Bio Announces the Appointment of Biotechnology Executive, John Varian, as Independent Board Member

Retrieved on: 
Tuesday, March 2, 2021
Biotechnology, General Health, Pharmaceutical, Health, Life sciences, Branches of biology, Biology, Biotechnology, Varian, Colony stimulating factor 1 receptor, Biopharmaceutical, Macrophage colony-stimulating factor, AmMax Bio, Inc., AMB-05X

AmMax Bio, Inc. (AmMax), a private clinical-stage biopharmaceutical company developing innovative treatments with its proprietary dual anti-inflammatory/anti-fibrotic therapeutic platform targeting the colony-stimulating factor 1 receptor (CSF1R), today announced that John Varian has been appointed as an Independent Board Member.

Key Points: 
  • AmMax Bio, Inc. (AmMax), a private clinical-stage biopharmaceutical company developing innovative treatments with its proprietary dual anti-inflammatory/anti-fibrotic therapeutic platform targeting the colony-stimulating factor 1 receptor (CSF1R), today announced that John Varian has been appointed as an Independent Board Member.
  • We are very happy to welcome John Varian to our Board at a time when AmMax is advancing its two lead programs into the clinic, said Larry Hsu, Ph.D., Chief Executive Officer of AmMax Bio.
  • Mr. Varian brings a wealth of industry experience to the Board of AmMax, having held leadership positions in business development, alliance management, capital fund-raising, and new product launches.
  • John has served as the CEO and director of XOMA, an antibody business, where he led the financial restructuring of the company.

Humanigen Expands its anti-GM-CSF Patent Portfolio

Retrieved on: 
Tuesday, March 2, 2021
Oncology, Health, Infectious diseases, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Cytokines, Granulocyte-macrophage colony-stimulating factor, EMR1, Colony-stimulating factor, Macrophage colony-stimulating factor, Macrophage

These two patents expand Humanigens patent portfolio and demonstrate the value of the companys pioneering approach to neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF).

Key Points: 
  • These two patents expand Humanigens patent portfolio and demonstrate the value of the companys pioneering approach to neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • Together, these patents continue to solidify Humanigens robust intellectual property portfolio which includes over 100 issued patents and over 50 patent applications.
  • Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.
  • In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

Humanigen to Present at Multiple Investor Conferences in March

Retrieved on: 
Thursday, February 25, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, Branches of biology, Clinical medicine, Immunology, Cytokines, Granulocyte-macrophage colony-stimulating factor, Cytokine release syndrome, Coronavirus disease, Macrophage colony-stimulating factor, EMR1, Cytokine, Acute respiratory distress syndrome

Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.

Key Points: 
  • Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • Humanigens immediate focus is to prevent or minimize the cytokine release syndrome that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection.
  • Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
  • In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.

AmMax Bio to Participate in the 41st Annual Cowen Health Care Conference

Retrieved on: 
Tuesday, February 16, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Colony stimulating factor 1 receptor, Cytokines, Macrophage colony-stimulating factor, Macrophage, Emactuzumab

AmMax Bio, Inc. (AmMax), a private clinical-stage biopharmaceutical company focused on developing first-in-class or best-in-class treatments with its proprietary dual anti-inflammatory/anti-fibrotic therapeutic platform targeting the colony-stimulating factor 1 receptor (CSF1R), today announced that Larry Hsu, Ph.D., Chief Executive Officer and the management team will participate in one-on-one meetings with investors at the 41st Annual Cowen Health Care Conference on Wednesday, March 3, 2021.

Key Points: 
  • AmMax Bio, Inc. (AmMax), a private clinical-stage biopharmaceutical company focused on developing first-in-class or best-in-class treatments with its proprietary dual anti-inflammatory/anti-fibrotic therapeutic platform targeting the colony-stimulating factor 1 receptor (CSF1R), today announced that Larry Hsu, Ph.D., Chief Executive Officer and the management team will participate in one-on-one meetings with investors at the 41st Annual Cowen Health Care Conference on Wednesday, March 3, 2021.
  • A potent monoclonal anti-CSF1R antibody, AMB-05X is a therapeutic platform targeting macrophage-driven diseases with significant unmet medical needs and substantial commercial potential.
  • Overactivation of the CSF1/IL-34 CSF1R axis substantially contributes to the inflammation and fibrosis inherent in many diseases.
  • Thus, the potent inhibition of CSF1R activity by AMB-05X represents a novel and powerful means of therapeutic intervention via its dual action.

Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium

Retrieved on: 
Friday, February 12, 2021
Branches of biology, Clinical medicine, Medicine, Breakthrough therapy, Orphan drugs, Cancer immunotherapy, Immune system, Clusters of differentiation, Atezolizumab, Checkpoint inhibitor, Colony stimulating factor 1 receptor, Macrophage colony-stimulating factor

The combination of derazantinib and atezolizumab is supported by preclinical data demonstrating derazantinibs strong inhibition of colony-stimulating-factor-1-receptor kinase (CSF1R).

Key Points: 
  • The combination of derazantinib and atezolizumab is supported by preclinical data demonstrating derazantinibs strong inhibition of colony-stimulating-factor-1-receptor kinase (CSF1R).
  • CSF1R inhibition may revert tumor-induced immunosuppression and thereby enhance the response to immune-checkpoint inhibition.
  • The following e-poster was presented at ASCO GU 2021:
    Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.
  • The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA.

Humanigen to Present and Participate at Multiple Upcoming Investor and Industry Conferences

Retrieved on: 
Thursday, February 11, 2021
Oncology, Health, Infectious diseases, General Health, Clinical trials, Pharmaceutical, Biotechnology, Branches of biology, Cytokines, Cell biology, EMR1, Granulocyte-macrophage colony-stimulating factor, Macrophage colony-stimulating factor

Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.

Key Points: 
  • Management will also participate in a Fireside Chat with Cantor Fitzgerald Analyst Louise Chen on February 26, 2021.
  • Humanigen believes that its GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection.
  • Humanigen is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity.
  • In addition, Humanigen is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders.